(firstQuint)Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNasein Patients With Cystic Fibrosis Previously Treated With Pulmozyme.

 This is a proof-of-concept, open label study, to evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of 2.

5 mg AIR DNase TM administered once daily for 28 days via inhalation to Cystic Fibrosis subjects who have previously been treated with Pulmozyme(R).

 This multicenter study will be conducted in approximately 10 sites and will enroll up to 15 subjects.

.

 Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNasein Patients With Cystic Fibrosis Previously Treated With Pulmozyme@highlight

This study evaluates the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase cent in Patients with Cystic Fibrosis previously treated with Pulmozyme(R).

